E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model

Molecular Cancer Therapeutics

Volumn 2, Issue 12, 2003, Pages 1313-1319

  Zhou, Zhichao ^a   Zhou, Rong Rong ^a   Guan, Hui ^a   Bucana, Corazon D ^a   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; E1A PROTEIN;

ANIMAL; APOPTOSIS; ARTICLE; DISEASE MODEL; EWING SARCOMA; GENE THERAPY; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NICK END LABELING; SURVIVAL RATE; VASCULARIZATION;

ADENOVIRUS E1A PROTEINS; ANIMALS; APOPTOSIS; BETA-GALACTOSIDASE; DISEASE MODELS, ANIMAL; GENE THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; NEOVASCULARIZATION, PATHOLOGIC; SARCOMA, EWING'S; SURVIVAL RATE;

EID: 4444221468     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Horowitz, M. E., Malawer, M. M., and Woo, S. Y. Ewing's sarcoma family of tumor: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In: P. A. Pizzo and D. G. Poplack (eds.), Principles and Practice of Pediatric Oncology, pp. 831-863. Philadelphia, PA: Lippincott-Raven Publishers, 1997.
2. Rosen, G., Forscher C. A., Mankin, H. J., and Selch, M. C. Bone tumors. In: J. F. Holland (ed.), Cancer Medicine, 4th ed., pp. 2503-2553. Baltimore, MD: W&W Waverly, 1997.
3. Kumar, R. and Fidler I. J. Angiogenic molecular and cancer metastasis. In Vivo, 18: 27-34, 1998.
4. Hortobagyi, G. N., Ueno, N. T., Xia, W., Zhang, S., Wolf, J. K., Putnam, J. B., Weiden, P. L., Willey, J. S., Carey, M., Branham, D. L., Payne, J. Y., Tucker, S. D., Bartholomeusz, C., Kilbourn, R. G., De Jager, R. L., Sneige, N., Katz, R. L., Anklesaria, P., Ibrahim, N. K., Murray, J. L., Theriault, R. L., Valero, V., Gershenson, D. M., Bevers, M. W., Huang, L., Lopez-Berestein, G., and Hung, M. C. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J. Clin. Oncol., 19: 3422-3433, 2001. (Pubitemid 32642196)
5. Villaret, D., Glisson, B., Kenady, D., Hanna, E., Carey, M., Gleich, L., Yoo, G. H., Futran, N., Hung, M. C., Anklesaria, P., and Heald, A. E. A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck, 24: 661-669, 2002. (Pubitemid 34734362)
6. Yoo, G. H., Hung, M. C., Lopez-Berestein, G., LaFollette, S., Ensley, J. F., Carey, M., Batson, E., Reynolds, T. C., and Murray, J. L. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin. Cancer Res., 7: 1237-1245, 2001. (Pubitemid 32708675)
7. Shao, R., Karunagaran, D., Zhou, B. P., Li, K., Lo, S. S., Deng, J., Chiao, P., and Hung, M. C. Inhibition of nuclear factor-κB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis. J. Biol. Chem., 272: 32739-32742, 1997. (Pubitemid 28023604)
8. Frisch, S. M. and Mymryk, J. S. Adenovirus-5 E1A: paradox and paradigm. Nat. Rev. Mol. Cell Biol., 3: 441-454, 2002.
9. Shao, R., Xia, W., and Hung, M. C. Inhibition of angiogenesis and induction of apoptosis are involved in E1A-mediated bystander effect and tumor suppression. Cancer Res., 60: 3123-3126, 2000. (Pubitemid 30407903)
10. Kuman, R. and Yarmand-Bagheri, R. The role of HER2 in angiogenesis. Semin. Oncol., 28: 27-32, 2001. (Pubitemid 33065107)
11. Yang, W., Klos, K., Yang, Y., Smith, T. L., Shi, D., and Yu, D. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer, 94: 2855-2861, 2002. (Pubitemid 34547683)
12. Izumi, Y., Xu, L., DiTomaso, E., Fukumura, D., and Jain, R. K. Herceptin acts as an antiangiogenic cocktail. Nature, 416: 279-280, 2002.
13. Zhou, Z., Jia, S-F., Hung, M. C., and Kleinerman, E. S. E1A sensitizes Her2/neu overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs. Cancer Res., 61: 3394-3398, 2001. (Pubitemid 32695031)
14. Zhou, R., Jia, S-F., Zhou, Z., Wang, Y., Bucana, C. D., and Kleinerman, E. S. Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16. Cancer Gene Ther., 9: 407-413, 2002. (Pubitemid 34438582)
15. Zhang, Y., Yu, D., Xia, W., and Hung, M. C. HER2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene, 10: 1947-1954, 1995.
16. Graham, F. L. and Prevec, L. Manipulation of adenovirus vector. Gene transfer and expression protocols. In: E. J. Murray (ed.), Methods in Molecular Biology: Gene Transfer and Expression Protocols, Vol. 7., pp. 109-128. Clifton, NJ: The Humana Press, 1991.
17. Koura, A. N., Liu, W., Kitadai, Y., Singh, R. K., Radinsky, R., and Ellis, L. M. Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by cell density. Cancer Res., 56: 3891-3894, 1996. (Pubitemid 26284734)
18. Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., and Semenza, G. L. Her2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol., 21: 3995-4004, 2001. (Pubitemid 32476461)
19. Plate, K. H., Breier, G., Weich, H. A., and Risau, W. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature, 359: 845-848, 1992.
20. Berkman, R. A., Merrill, M. J., Reinhold, W. C., Monacci, W. T., Saxena, A., Clark, W. C., Robertson, J. T., Ali, I. U., and Oldfield, E. H. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J. Clin. Invest., 91: 153-159, 1993. (Pubitemid 23037267)
21. Toi, M., Kondo, S., Suzuki, H., Yamamoto, Y., Inada, K., Imazawa, T., Taniguchi, T., and Tominaga, T. Quantitative analysis of vascular endothelial growth factor in primary breast carcinoma. Cancer, 77: 1101-1106, 1996. (Pubitemid 26080900)
22. Maeda, K., Chung, Y., Ogawa, Y., Takasuka, S., Sawada, T., and Sowa, M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer, 77: 858-863, 1996. (Pubitemid 26061277)
23. Takano, S., Yoshio, Y., Kondo, S., Suzuki, H., Maruno, T., Shirai, S., and Nose, T. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res., 56: 2185-2190, 1996. (Pubitemid 26119923)
24. Takahashi, A., Sasaki, H., Kim, S. J., Tobisu, K. I., Kakizoe, T., Tsukamoto, T., Kumamoto, Y., Sugimura, T., and Terada, M. Markedly increased amounts of mRNAs for vascular endothelial growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res., 54: 4233-4237, 1994. (Pubitemid 24258135)
25. Claffy, P. K., Brown, L. G., del Aguila, L. F., Tognazzi, K., Yeo, K., Manceau, E. J., and Dvorak, H. F. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis and experimental metastases. Cancer Res., 56: 172-181, 1996. (Pubitemid 26010397)
26. Xiong, S., Grijalva, R., Zhang, L., Nguyen, N. T., Pisters, P. W., Pollock, R. E., and Yu, D. Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-β1-activated p38 signaling pathway enhances endothelial cell migration. Cancer Res., 61: 1727-1732, 2001. (Pubitemid 34292611)
27. Suzuki, K., Hayashi, N., Miyamoto, Y., Yamamoto, M., Ohkawa, K., Ito, Y., Sasaki, Y., Yamaguchi, Y., Nakase, H., Noda, K., Enomoto, N., Arai, K., Yamada, Y., Yoshihara, H., Tujimura, T., Kawano, K., Yoshikawa, K., and Kamada, T. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res., 56: 3004-3009, 1996. (Pubitemid 26199745)
28. Yamamoto, Y., Toi, M., Kondo, S., Matsumoto, T., Suzuki, H., Kitamura, M., Tsuruta, K., Taniguchi, T., Okamoto, A., Mori, T., Yoshida, M., Ikeda, T., and Tominaga, T. Concentration of vascular endothelial growth factor in the sera of normal control and cancer patients. Clin. Cancer Res., 2: 821-826, 1996. (Pubitemid 26168934)
29. Kumar, H., Heer, K., Lee, P. W., Duthie, G. S., MacDonald, A. W., Greenman, J., Kerin, M. J., and Monson, J. R. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin. Cancer Res., 4: 1279-1285, 1998. (Pubitemid 28213341)
30. Holzer, G., Obermair, A., Koschat, M., Preyer, O., Kotz, R., and Trieb, K. Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors. Med. Pediatr. Oncol., 36: 601-604, 2001. (Pubitemid 32402155)
31. Hortobagyi, G. N., Hung, M. C., and Lopez-Berestein, G. A phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer. Hum. Gene Ther., 9: 1775-1798, 1998.